Xellia Pharmaceuticals Appoints Peter Baker as Chief Commercial Officer, Xellia North America
Retrieved on:
Wednesday, September 11, 2019
Xellia Pharmaceuticals (Xellia), a global leader in the manufacturing of specialty anti-infective treatments, has appointed Peter Baker as Chief Commercial Officer for Xellia North America to prepare for the continued expansion and growth of its innovative pipeline.
Key Points:
- Xellia Pharmaceuticals (Xellia), a global leader in the manufacturing of specialty anti-infective treatments, has appointed Peter Baker as Chief Commercial Officer for Xellia North America to prepare for the continued expansion and growth of its innovative pipeline.
- View the full release here: https://www.businesswire.com/news/home/20190911005414/en/
Xellia Pharmaceuticals Appoints Peter Baker as Chief Commercial Officer, Xellia North America (Photo: Business Wire)
Craig Boyd, Xellias North American President said,
Since we established our US commercial office a year ago, Xellia has secured a leading market presence in generic injectable anti-infectives. - We are already the leading US supplier of Colistimethate Sodium and Bacitracin, and the third largest US supplier of Vancomycin, under the Xellia brand.
- Mr. Baker was until now the national accounts lead for Xellia North America, building key customer relationships, including Xellias product supply agreement with Civica Rx announced in May 2019.